semaj83/ctmatch_classification huggingface dataset:
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Emphysema Pulmonary Disease, Chronic Obstructive for All Participants Able to read and write English At least 30 pack-year smoking history (the equivalent of smoking a pack a day for 30 years) Able to participate in the informed consent process Relatively stable clinical status for the past six weeks (i.e., no illness in the 6 weeks before study entry) for Participants with Emphysema Global Initiative for Chronic Obstructive Lung Disease (GOLD) class II, III, or IV COPD, as determined by post-bronchodilator spirometry values OR More than minimal emphysema on an acceptable-quality chest CT scan for Participants without Emphysema GOLD class I COPD or GOLD class 0 (2005 classification), as determined post-bronchodilator spirometry values AND  Pregnant Prisoner Vulnerable populations Recent illness (defined as increased cough, sputum production, worsening malaise, or need for unscheduled physician visit in the 6 weeks prior to enrollment) Coexisting active chronic inflammatory or collagen vascular disease, immunodeficiency of any kind, non-cutaneous malignancy (melanoma is an exclusion), or previous organ transplant Congenital abnormalities of the lung or previous lung surgery Known active hepatitis B, hepatitis C, or HIV/AIDS (not prospectively evaluated) CT evidence of lung disease other than emphysema (including significant fibrosis, bronchiectasis, consolidation, or indeterminate nodules)
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Phase 1 & Gene Expression: --Current hospitalization for COPD exacerbation Phase 1 & 2: COPD & ONE of the following History of hospitalization for COPD exacerbation, OR Currently on supplemental oxygen, OR History of evaluation for lung transplant or LVRS, OR >/= 6 months post-LVRS Phase 1 or 2 Current or former smoker, >/= 20 pack-yr. smoking history FEV1 </= 70%; FEV1/FVC </= 70% Life expectancy of > 6 months  < 20 pack-yr. smoking history Diagnosis of pulmonary fibrosis, bronchiectasis, mediastinal mass, or presence of a pulmonary mass Asthma FEV1 > 70% or FEV1/FVC >70%
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD COPD, smoker COPD, non smoker
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Chronic Obstructive Pulmonary Disease Age 18-75 years Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of the 5 groups described above Able to stop smoking for 10 days and start smoking 3-4 cigarettes within 1 hour Physically and mentally able to undergo the total study protocol Written informed consent  Participation in another study Alpha-1-antitrypsin deficiency Selected grade 1-3 co-morbidity listed in the ACE-27 Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis Active extra-pulmonary infection like hepatitis A-C, cystitis, gastro-enteritis etc Pulmonary diseases like sarcoidosis, IPF, silicosis, hypersensitivity pneumonitis Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukaemia etc Medication that may affect the results of the study: NSAID's, immunosuppressive agents like prednisolon, metotrexate, azathioprine,Acenocoumarol
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Right Heart Failure Cor Pulmonale Hospitalized patients Adults Right heart failure secondary to pulmonary hypertension (cor pulmonale) Pronounced leg edema  Patients in sepsis Hemodynamically unstable Renal failure (creatinine >2 mg%) Deep vein thrombosis Pregnancy Psychiatric/noncompliant patients Patients who will not sign the informed consent form
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dyspnea Heart Failure Asthma COPD patient had to present with shortness of breath as the primary complaint (defined as either the sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea)  age <18 years history of renal insufficiency, trauma, severe coronary ischemia (unless patient's predominant presentation was dyspnea), and other causes of dyspnea pneumonia pulmonary embolism carcinoma pneumothorax pleural effusion intoxications (drugs) anaphylactic reactions upper airway obstruction
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Smoking Smoking Cessation Chronic Bronchitis Emphysema Group A Healthy nonsmokers Enrolled in the "Normal" protocol #0005004439 "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy" Healthy according to the "Normal" protocol #0005004439 Willing and able to provide informed consent for the long term follow up study with repeated bronchoscopies Male and Female subject ≥18 years of age smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study Group B Healthy current smokers Enrolled in the "Normal" protocol #0005004439  Groups A Unable to provide proper informed consent Drug and/or alcohol abuse within the past six months Individuals with asthma and with recurrent or recent (within three months) and/or acute pulmonary infection Allergy to lidocaine Significant kidney disease or subjects on dialysis Females who are pregnant or lactating or intending to become pregnant in the next 12 months Major depression or other significant psychiatric disorder HIV+ Subjects that have unstable coronary artery disease as evidenced by unstable angina, >Class II NYHA cardiac status, history of congestive heart failure or MI within the last 12 months
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Cardiovascular Disease Smoking Bronchodilation COPD Gold stage II-III (FEV1/FVC<0,70 and FEV1 30-80% of predicted value) Current cigarette smoking (at the time of performing the study) Willing to provide written informed consent Refrain from smoking and bronchodilators > 8 hours (depends on treatment) before the test Registered in one of the recruitment institutes  COPD gold stage I or IV Asthmatic component: History of asthma, present asthma by complaints, eosinophilia or reversibility ≥ 10% of predicted Unable to communicate Physically unable to perform any of the tests Non-COPD respiratory disorders Previous lung-volume reduction surgery and/or lung transplantation Evidence of alcohol, drug or solvent abuse Known α-1 antitrypsin deficiency
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease Nocturnal Desaturation Patients with a diagnosis of COPD supported by a history of past smoking and obstructive disease: FEV1<70% predicted, FEV1/FVC<70% and a total lung capacity by body plethysmography >80% predicted Stable COPD at study entry, as demonstrated by (1) no acute exacerbation and (2) no change in medications for at least 6 weeks before enrollment in the trial Non-smoking patients for at least 6 months before enrollment in the trial SpO2 at rest < 95% Patients fulfilling the current definition of nocturnal oxygen desaturation, i.e., >=30% of the recording time with transcutaneous arterial oxygen saturation <90% on at least one of two consecutive recordings Ability ot give informed consent  Patients with severe hypoxemia fulfilling the usual for continuous oxygen therapy at study entry: PaO2 <=55 mmHg; or PaO2 <= 59 mmHg with clinical evidence of at least one of the following: (1) with right ventricular hypertrophy (P pulmonale on ECG:3 mm leads ll, lll, aVf); (2) right ventricular hypertrophy; (3)Peripheral edema (cor pulmonale); (4) hematocrit >=55% Patients with proven sleep apnea (defined by an apnea/hypopnea index of >=15 events/hour) or suspected sleep apnea on oximetry tracings Patients currently using nocturnal oxygen therapy Patients with known left heart or congenital heart diseases, interstitial lung diseases, bronchiectasis as the main cause of obstructive disease, lung carcinoma, severe obesity (body mass index >= 40 kg/m²), or any other disease that could influence survival
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  NSCLC Dyspnea Histologically or cytologically proven incurable stage IIIb or stage IV non-small cell lung cancer Dyspnea as defined by a score of 2 or higher on the 10-point Dyspnea Numeric Scale (Appendix 2) New dyspnea or worsening dyspnea within the last 6 months per patient reporting  Age < 18 An FEV1 / FVC ratio < 0.7 with an FEV1 of < 80% predicted post-bronchodilator Life expectancy < 3 months Significant worsening of dyspnea over the last week such that an acute cardiac or respiratory condition is considered likely (e.g. pneumonia, heart failure) Myocardial infarction within the previous month Heart rate ≥ 120 Active tuberculosis or tuberculosis receiving antibiotic therapy Current or previous use of ipratropium, tiotropium, or oxitropium (see Appendix 6) Sensitivity to atropine Pre-existing diagnosis of asthma or moderate to severe Chronic Obstructive Pulmonary Disease
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Signed informed consent Age ≥ 40 years Patients fulfilling for COPD according to the Global initiative for chronic obstructive pulmonary disease (GOLD) stage I or higher Smokers or ex-smokers of at least 10 pack-years Patients suffering an either Admitted to hospital due to (severe exacerbation) or Confirmed at GP (general practitioner) setting (moderate exacerbation) Definition Increase in respiratory symptoms requiring treatment with oral corticosteroids, antibiotics or both  Patients who have never smoked Patients with active long-term respiratory disease (e.g. bronchial asthma, cystic fibrosis, severe bronchiectasis, malignancy, restrictive lung diseases etc.) Exacerbation of COPD due to other causes such as pneumothorax and acute decompensated congestive heart failure Difficulties in communication (cognitive deterioration, sensorial disability, language barriers) Severe disease with poor vital prognosis (life length expectancy less than one year)
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Type of subject: Outpatients Informed consent: Subjects must give their signed and dated written informed consent to participate Gender: Male or Female Age: 40 years of age or older at Visit 1 COPD diagnosis: Documented diagnosis of COPD at least 6 months prior to Visit 1 in accordance with the following definition by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline: Post bronchodilator FEV1/FVC < 0.7 History of exacerbations: At least one COPD exacerbation which required the use of any additional treatment in the last 12 months prior to Visit 1 For subjects who were diagnosed between 6 to 12 months prior to Visit 1, they should have at least one COPD exacerbation that required the use of any additional treatment since diagnosis Tobacco use: Smokers or ex-smokers with a smoking history of more than 10 pack years  Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study Asthma: Subjects with a current diagnosis of asthma. Subjects with a prior history of asthma are eligible if COPD is the current diagnosis Non-compliance: Subjects unable to comply with any aspect of this study protocol or scheduled visits to the study centre
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Chronic Obstructive Airway Disease Asthma Chronic Cough General Adult subjects aged 18 years and over Meet for subject groups as outlined below (1) Healthy volunteers Non-smokers No history of respiratory disease (2) Healthy smokers Current smokers with smoking history of ≥10 pack years Spirometry within normal limits i.e. FEV1>80% predicted and FEV1/FVC ratio >75% predicted (3) Asthma  Symptoms of upper respiratory tract infection within the last 6 weeks 2) Participation in another clinical trial of an investigational drug within the last 4 weeks 3) Use of medication likely to alter cough reflex sensitivity i.e. ACE inhibitors, codeine phosphate, morphine sulphate, 4) Patients with severe respiratory disease i.e. FEV1 < 1 litre, 5) Significant medical co-morbidities likely to affect ability to participate in the trial or affect cough reflex sensitivity e.g. diabetes, stroke, Parkinson's disease, multiple sclerosis etc
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  COPD Main Willingness to sign a written informed consent Chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009 Chinese or Malay or Indian ethnicity History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0 Forced expiratory volume in the first second/ Forced vital capacity (FEV1/FVC) ratio (post-bronchodilator) < 70% Forced expiratory volume in the first second (FEV1) (post-bronchodilator) < 50 % of predicted Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years Main  Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0 Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0 History of asthma diagnosis in patients < 40 years of age or relevant lung disease other than COPD Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0 Known alpha-1-antitrypsin deficiency
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease age 40-80 years old cases: spirometry (post-bronchodilator) based diagnosis of COPD (GOLD criteria) + smoking history of at least 10 pack-years and active smoking behavior till at least 10 years from the moment of enrollment smoking controls: no COPD (spirometry based) + smoking history of at least 10 pack-years and active smoking behavior till at least 10 years from the moment of enrollment non-smoking controls: no COPD (spirometry based) + < 1 pack year  Respiratory disorder other than COPD α1-antitrypsin deficiency Known history of significant inflammatory disease other than COPD COPD exacerbation within 4 weeks prior to study Lung surgery Recent diagnosis of cancer Therapy with oral corticosteroids in the last 6 weeks Significant cardiovascular comorbidity Significant orthopedic/musculoskeletal problems
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 21.0-70.0,  Pulmonary Disease, Chronic Obstructive Asthma A subject will be eligible for in this study only if all of the following apply All volunteers must be aged between 21 to 70 years inclusive and be competent to understand and give informed consent All female volunteers of child bearing potential must have provided a negative pregnancy test before and prior to any HRCT scan Body weight < 120 kg and BMI within the range 18 kg/m2 (inclusive) Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form Available to complete the study Subject will then be included only if they fulfil all for the following relevant cohort Healthy: Cohort Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history and physical. A subject with a clinical abnormality or parameters outside the reference range for the population being studied may be included if the Investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures Non-smokers (never smoked or not smoking for >12 months with <1 pack year history) (Pack years = (cigarettes per day smoked/20) x number of years smoked))  A subject will not be eligible for in this study if any of the following apply As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study Any pregnant female Volunteers who have a past or present disease, which as judged by the Investigator, may affect subject safety or influence the outcome of the study The subject has received an investigational drug or participated in any other research trial within 30 days or five half-lives, or twice the duration of the biological effect of any drug (whichever is longer) The subject that has both asthma and COPD Previous in a research and/or medical protocol involving nuclear medicine Any Radiological investigations with significant radiation burden (a significant radiation burden being defined as ICRP category IIb or above: No more than 10 mSv in addition to natural background radiation, in the previous 3 years including the dose from this study) The subject has a history of alcohol or drug abuse The subject has had a respiratory tract infection within four weeks of the start of the study